Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

MLA

Nader Najafian, et al. “Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.” Clinical Pharmacokinetics, vol. 60, Oct. 2020, pp. 365–78. EBSCOhost, https://doi.org/10.1007/s40262-020-00940-9.

APA

Nader Najafian, Gabriel J. Robbie, Varun Goel, Anna Borodovsky, Prajakta S. Badri, Jae Kim, Bahru A. Habtemariam, Xuemin Jiang, & Valerie A. Clausen. (2020). Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical Pharmacokinetics, 60, 365–378. https://doi.org/10.1007/s40262-020-00940-9

Chicago

Nader Najafian, Gabriel J. Robbie, Varun Goel, Anna Borodovsky, Prajakta S. Badri, Jae Kim, Bahru A. Habtemariam, Xuemin Jiang, and Valerie A. Clausen. 2020. “Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.” Clinical Pharmacokinetics 60 (October): 365–78. doi:10.1007/s40262-020-00940-9.